I agree with the timeline described by Jellyroll.
Bariatric surgery will be reimbursed if individuals fail lifestyle interventions. Add the time on the weighting list, and then the time to reduce weight, it's at least two years. Given the importance of protecting sight and minimising complications of raised ICP, Presendin will continue to have chronic use even after the surgery. Plus, GLP-1 have the added benefit of reducing weight, so it's another reason that patients will stay on it.
Invex estimated the average duration of time Presendin will be used for patients would be 4.3 years. I think that even with Bariatric surgery, this number will stay true.
I agree with the timeline described by Jellyroll. Bariatric...
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.763M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 84879 | 7.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 7400 | 2 |
View Market Depth
| Last trade - 16.12pm 11/11/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable